Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US2183521028
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BF8JD9
CORT
Corcept Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Corcept Therapeutics Inc
ISIN
US2183521028
TICKER
CORT
MIC
XNAS
REUTERS
CORT.OQ
BLOOMBERG
CORT US
Sat, 11.04.2026       Corcept Therapeutics
US2183521028

NEW YORK and NEW ORLEANS, April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics I...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented final overall survival data from its pivotal Phase 3 ROSELLA trial of L...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Corcept Therapeutics
US2183521028

CORT Investors with Losses Encouraged to Contact FirmSAN FRANCISCO, April 7, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026....
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Corcept Therapeutics
US2183521028

BENSALEM, Pa., April 7, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CORCEPT THERAPEUTICS...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT). Shareholders who purchased shares of CORT during the class period listed are e...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 7, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, in...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If you...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 06.04.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) have opportunity to lead the securities fraud class action lawsuit....
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereu...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissio...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       Corcept Therapeutics
US2183521028

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, onco...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       Corcept Therapeutics
US2183521028

NEW ORLEANS, April 3, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) ("Corcept" or the "Company"), if they purchased or otherwise acquir...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       Corcept Therapeutics
US2183521028

SAN FRANCISCO, April 3, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026....
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - April 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Corcept Therapeutics
US2183521028

SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026....
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 01.04.2026       Corcept Therapeutics
US2183521028

NEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT) of a class action securities lawsuit. CLAS...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Corcept Therapeutics
US2183521028

NEW YORK, March 31, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, i...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, March 31, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT)....
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Corcept Therapeutics
US2183521028

NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT). Shareholders who purchased shares of CORT during the class period listed are...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Corcept Therapeutics
US2183521028

Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 DeadlineSAN FRANCISCO, March 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, March 30, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated there...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissi...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented late-breaking data from its MOMENTUM trial examining the prevalence of...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If you...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       Corcept Therapeutics
US2183521028

NEW YORK and NEW ORLEANS, March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics I...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Corcept Therapeutics
US2183521028

NEW YORK, March 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, in...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Corcept Therapeutics
US2183521028

Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 DeadlineSAN FRANCISCO, March 26, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Corcept Therapeutics
US2183521028

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Corcept Therapeutics
US2183521028

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli™...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Corcept Therapeutics
US2183521028

NEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT) of a class action securities lawsuit. CLA...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If you...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Corcept Therapeutics
US2183521028

BENSALEM, Pa., March 24, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CORCEPT THERAPEUTIC...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Corcept Therapeutics
US2183521028

Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 DeadlineSAN FRANCISCO, March 24, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Corcept Therapeutics
US2183521028

NEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT). Shareholders who purchased shares of CORT during the class period listed are...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Corcept Therapeutics
US2183521028

Lead Plaintiff Deadline is April 21, 2026NEW YORK, March 24, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed against on behalf of all persons and entities that purchased or otherwise Corcept Therapeutics Incorporated (NASDAQ: CORT) ("Corcept" or the 'Company...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) have opportunity to lead the securities fraud class action lawsuit....
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissi...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated there...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - March 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: If you...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 21.03.2026       Corcept Therapeutics
US2183521028

NEW ORLEANS, March 20, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) ("Corcept" or the "Company"), if they purchased or otherwise acqui...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Corcept Therapeutics
US2183521028

Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 DeadlineSAN FRANCISCO, March 20, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated there...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Corcept Therapeutics
US2183521028

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissi...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Corcept Therapeutics
US2183521028

New York, New York--(Newsfile Corp. - March 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline.SO WHAT: I...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Corcept Therapeutics
US2183521028

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquir...
Read more
Corcept Therapeutics
Technical Analysis Termsheets Terminal
Permalink